IQV · Iqvia Holdings Inc.
$236.66
-4.86 (-2.01%)
At close · Aug 14
Market Cap
$39.50B
Shares
166.90M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$236.66
Open$240.55
Day$235.87–243.00
52W close$156.66–247.56
Avg vol 30d1.4M
Short int4.6M · 2.7% float · 2.7d
Short vol32%
Last earningsJul 28, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 28
Up next
Next earnings call
Oct 30, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 28, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+19%
above
Price vs 50-day avg
+15%
above
RSI (14)
60
neutral
MACD trend
Negative
52-week position
88%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+15%
trailing
6-month return
+46%
trailing
YTD return
+5%
this year
Relative strength
+32%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $206 › 200d $199 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +130 funds added
Insider flow
Distributing
Net -$29.2M over 90 days · 100% sells
Short interest
Falling
2.73% of float · ▼ -13.3% MoM · 2.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1,063 holders — mid 3-yr range
Squeeze score
46
elevated · 0–100
Fundamentals
Revenue growth
+42%
Y/Y
EPS growth
+5%
Y/Y
Valuation
P/E 29.4
below peers
Buyback
$2.8B
remaining
Balance sheet
$13.7B
net debt
Quant / Vol
risk profile
Volatility
41%
annualized · 1-yr
Max drawdown
−36%
past year
ATR
3.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 28, 2026
Revenue
· full-year 2026
$17.28B – $17.48B
Adjusted EBITDA
· full-year 2026
Non-GAAP
$4B – $4.05B
Adjusted Diluted Earnings per Share
· full-year 2026
Non-GAAP
$12.80 – $13.00
Prior guidance
period ended
· from the Earnings Call filed Jun 30, 2024
Revenue
· full year
$15.43B – $15.53B
Adjusted EBITDA
· full year
$3.71B – $3.77B
Adjusted EBITDA
· third quarter
$925M – $950M
Adjusted diluted earnings per share
· full year
$11.10 – $11.30
Revenue
· third quarter
$3.83B – $3.88B
Adjusted diluted EPS
· third quarter
$2.76 – $2.86
Guided vs delivered
· last 2 settled
Total revenue
full year 2024
guided $15.4B – $15.65B
$15.41B
In line
Total revenue
first quarter 2024
guided $3.65B – $3.73B
$3.74B
Beat +1.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+19%
Bullish
Price vs 50-day avg
+15%
Bullish
RSI (14)
60
Neutral
MACD trend
Negative
Bearish
52-week position
88%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $206 › 200d $199 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +130 funds added
Insider flow
Distributing
Net -$29.2M over 90 days · 100% sells
Short interest
Falling
2.73% of float · ▼ -13.3% MoM · 2.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1,063 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $157
Now $237 · 88%
Range high $248
vs 200-day avg +19%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net Leverage Ratio non-GAAP | 3.59 | As of June 30, 2026 | — |
| R&D Solutions contracted backlog | $34.2B | As of June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $932M | Q1 2026 | — |
|
|
|||
| Book-to-bill ratio | 1.04 | Q1 2026 | — |
|
|
|||
| Free Cash Flow non-GAAP | $491M | Q1 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net Cash provided by Operating Activities 618M
-127M Acquisition of property, equipment and software
= Free Cash Flow 491M
|
|||
| R&D Solutions Net New Bookings | 2.5B | Q1 2026 | — |
| Trailing-twelve-month book-to-bill ratio | 1.11 | Q1 2026 | — |
| Adjusted Diluted Earnings per Share non-GAAP | $11.92 | the full year | — |
| Adjusted Net Income non-GAAP | $2.07B | the full year | — |
GAAP → non-GAAP reconciliationGAAP Net Income Attributable to IQVIA Holdings Inc. 1.36B
+252M Provision for income taxes
+543M Purchase accounting amortization
-22M Income in unconsolidated affiliates
+1M Income from noncontrolling interests
+247M Stock-based compensation
-63M Other income, net
+6M Loss on extinguishment of debt
+166M Restructuring and related expenses
+32M Acquisition related expenses
-453M Adjusted tax expense
-1M Income from noncontrolling interests (Adjusted Net Income)
= Adjusted Net Income 2.07B
|
|||
| R&D Solutions quarterly bookings | $2.7B | the fourth quarter | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IQV
this stock
Iqvia Holdings Inc.
|
$39.50B | +5.0% | +41.6% | 29.4 | 2.7% |
|
TMO
Thermo Fisher Scientific Inc.
|
$222.96B | +1.5% | +14.5% | 32.4 | 1.3% |
|
DHR
Danaher Corp /De/
|
$142.32B | -11.6% | +8.5% | 35.9 | 1.7% |
|
NTRA
Natera, Inc.
|
$45.54B | +35.3% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.41B | -18.6% | +10.4% | 38.7 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IQV | -0.9% | +14.7% | +45.8% | +0.7% | +5.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -1.3% | +10.3% | +32.0% | -3.2% | -8.9% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$15.72B
Spent (derived)
$12.91B
Remaining
$2.82B
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1478242
CUSIP
46266C105
13F (30d)
1009 filings
977 filers
Visit website
Investor relations